drugset / Trial / NCT00362479

Open-Label Study to Evaluate the Safety and Efficacy of a Low-Dose 28-Day Oral Contraceptive

NCT00362479

Phase 3 Completed 1347 enrolled Duramed Research
Non-randomizedSingle-groupOpen-labelPrevention

Summary

This is an open-label, single treatment study. All subjects will receive 6 months of oral contraceptive therapy with DR-1021. Study participants will receive physical and gynecological exams, including Pap smear. During the study, all participants will be required to complete a diary.

Timeline

Start
2006-08
Primary completion
2007-07
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject DR-1021 Unknown Oral

Indications

No indication recorded.